HCPLive Network

Phase 3 Trial of Experimental Gout Drug Lesinurad to Begin

Phase 3 Trial of Experimental Gout Drug Lesinurad to BeginArdea Biosciences announced on Monday that it would soon begin the first of four planned Phase 3 clinical trials of its experimental gout drug lesinurad. The trial is expected to include around 2,000 gout patients at study sites around the world.
 
Lesinurad is an oral inhibitor of the URAT1 transporter in the kidney that regulates uric acid excretion. According to a press release from Ardea Biosciences, around 90% of gout patients are thought to excrete too little uric acid, and studies have found that defective renal transporters, which promote excretion of uric acid under normal circumstances, are genetically linked to gout.
 
Since currently available gout drugs such as the xanthine oxidase inhibitors allopurinol and febuxostat have a mechanism of action different from URAT1 inhibitors, the hope is that lesinurad will be able to be used in conjunction with these other drugs to help the many gout patients who are not adequately treated with existing therapies alone. In previous Phase 1 and 2 trials, lesinurad has been tested on over 700 patients as a single agent and in combination with allopurinol and febuxostat.

Further Reading
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Access to an employer-sponsored private price transparency platform is associated with reduced total claims payments, according to research published in the Oct. 22/29 issue of the Journal of the American Medical Association.
Study results show that eluxadoline may be useful in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) who do not achieve symptom relief with loperamide.
Research presented at the European League Against Rheumatism’s Annual Meeting indicates comorbid diabetes may be linked to increased osteoarthritis pain.
Medications commonly used to treat Parkinson's disease may raise the risk of impulse control disorders such as compulsive gambling, compulsive shopping, and/or hypersexuality, according to a new review published online Oct. 20 in JAMA Internal Medicine.
A state law that requires plaintiffs to release relevant protected health information before proceeding with allegations of medical liability has been upheld by a federal appeals court, according to the American Medical Association.
High-dose supplementation with resveratrol improves bone mineral density in obese men with metabolic syndrome, according to a study published online Oct. 16 in the Journal of Clinical Endocrinology & Metabolism.
More Reading